Observational studyHaematologica2022

Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study.

Marco Cerrano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.